LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?Zacks Investment Research • 09/17/26
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.The Motley Fool • 09/17/26
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 09/16/26
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight LossMarketBeat • 09/15/26
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?Zacks Investment Research • 09/11/26
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/10/26
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/10/26
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.The Motley Fool • 09/10/26
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.The Motley Fool • 09/06/26
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 09/03/26
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're WrongThe Motley Fool • 09/03/26
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.The Motley Fool • 08/30/26
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?Zacks Investment Research • 08/28/26
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?The Motley Fool • 08/27/26
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?Zacks Investment Research • 08/17/26
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)Seeking Alpha • 08/07/26
Viking Therapeutics Declined in July, and why its Long-Term Prospects are UndiminishedThe Motley Fool • 08/06/26
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetThe Motley Fool • 07/30/26